{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:00:52Z","timestamp":1777320052301,"version":"3.51.4"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>The main objective of this study was to evaluate the effect of CYP2B6 and CYP3A4 polymorphisms on the virological and immunologic responses of HIV patients. A total of 153 HIV-positive patients were enlisted for the study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and methods<\/jats:title>\n            <jats:p>Viral load and median CD4 T cell counts were evaluated at baseline and month 6 (M6). Samples were identified using TaqMan genotyping assays.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The AG in CYP2B6 rs2279343 was associated with VLS compared to homozygous AA. In the dominant model, the AG\/GG genotypes were associated with VLS compared to the AA genotype. Moreover, in overdominant model, the AG genotype was associated with VLS compared to AA\/GG. Regarding immunological response, only the AG in SNP rs2279343 CYP2B6 was associated with an increase in CD4 cell count between baseline and M6. In CYP2B6 rs3745274, the CD4 cell count at M6 was higher than that of baseline for GG carriers and for GT carriers. In CYP3A4 rs2740574, the TC carriers showed a higher median CD4 count at M6 compared to that of the baseline count, as well as for CC carriers. The best genotypes combination associated with CD4 cell count improvement were AA\/AG in SNP rs2279343 and GG\/GT in SNP rs3745274.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our findings support the fact that CYP2B6 rs2279343 could help in the prediction of VLS and both SNPs rs3745274 and rs2279343 in CYP2B6 and CYP3A4 rs2740574 were associated with immune recovery in Malian HIV-positive patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000477","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T12:11:34Z","timestamp":1658232694000},"page":"219-225","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen"],"prefix":"10.1097","volume":"32","author":[{"given":"Yaya","family":"Kassogue","sequence":"first","affiliation":[{"name":"Department of Anatomo-pathology, University Hospital of Point G"},{"name":"Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G"},{"name":"Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brehima","family":"Diakite","sequence":"additional","affiliation":[{"name":"Department of Anatomo-pathology, University Hospital of Point G"},{"name":"Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G"},{"name":"Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoudou","family":"Maiga","sequence":"additional","affiliation":[{"name":"Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G"},{"name":"Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako"},{"name":"Department of Biomedical Engineering, Northwestern University, Evanston, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oumar","family":"Kassogue","sequence":"additional","affiliation":[{"name":"Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issa","family":"Konate","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako"},{"name":"Department of Infectious Diseases and Tropical Medicine, University Hospital of Point G"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadidiatou","family":"Tamboura","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Tropical Medicine, University Hospital of Point G"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fousseyni","family":"Diarra","sequence":"additional","affiliation":[{"name":"Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoumana","family":"Diarra","sequence":"additional","affiliation":[{"name":"Center of Listening, Care, Animation, and Counseling for People Living With HIV"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahamadou Karamoko","family":"Sawadogo","sequence":"additional","affiliation":[{"name":"Center of Listening, Care, Animation, and Counseling for People Living With HIV"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaya","family":"Goita","sequence":"additional","affiliation":[{"name":"Department of Medical Biology and Anatomo-pathology, University Hospital, Mali Hospital"},{"name":"Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidi Boula","family":"Sissoko","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako"},{"name":"Department of Cytogenetics and Reproductive Biology, National Institute for Public Health Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adama Seydou","family":"Sissoko","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako"},{"name":"Department of Neurology, University Hospital of Point G"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nouhoum","family":"Guirou","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako"},{"name":"Institute of Tropical Ophthalmology of Africa, Bamako, Mali"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hind","family":"Dehbi","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Pathology Laboratory, Faculty of Medicine and Pharmacy of Casablanca, University Hassan II"},{"name":"Medical Genetics Laboratory, Ibn Rochd University Hospital Center, Casablanca, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sellama","family":"Nadifi","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Pathology Laboratory, Faculty of Medicine and Pharmacy of Casablanca, University Hassan II"},{"name":"Medical Genetics Laboratory, Ibn Rochd University Hospital Center, Casablanca, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sekou","family":"Bah","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako"},{"name":"Department of pharmacy, University Hospital of Point G, Bamako, Mali"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheick Bougadari","family":"Traore","sequence":"additional","affiliation":[{"name":"Department of Anatomo-pathology, University Hospital of Point G"},{"name":"Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G"},{"name":"Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bakarou","family":"Kamate","sequence":"additional","affiliation":[{"name":"Department of Anatomo-pathology, University Hospital of Point G"},{"name":"Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G"},{"name":"Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sounkalo","family":"Dao","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako"},{"name":"Department of Infectious Diseases and Tropical Medicine, University Hospital of Point G"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guimogo","family":"Dolo","sequence":"additional","affiliation":[{"name":"Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G"},{"name":"Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"R2-20250808","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/cts.13120","article-title":"Large variability in plasma efavirenz concentration in Papua New Guinea HIV\/AIDS patients associated with high frequency of CYP2B6 516T allele.","volume":"14","author":"Bordin Andriguetti","year":"2021","journal-title":"Clin Transl Sci"},{"key":"R3-20250808","doi-asserted-by":"crossref","first-page":"1990527","DOI":"10.1080\/20008198.2021.1990527","article-title":"HIV\/AIDS stigma and psychological well-being after 40 years of HIV\/AIDS: a systematic review and meta-analysis.","volume":"12","author":"Rzeszutek","year":"2021","journal-title":"Eur J Psychotraumatol"},{"key":"R4-20250808","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3851\/IMP3223","article-title":"Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015.","volume":"23","author":"Bengtson","year":"2018","journal-title":"Antivir Ther"},{"key":"R5-20250808","doi-asserted-by":"crossref","first-page":"18757","DOI":"10.7448\/IAS.16.1.18757","article-title":"The next generation of the World Health Organization\u2019s global antiretroviral guidance.","volume":"16","author":"Hirnschall","year":"2013","journal-title":"J Int AIDS Soc"},{"key":"R6-20250808","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00228-018-2499-0","article-title":"Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.","volume":"74","author":"Mugusi","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"R7-20250808","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/cid\/civ155","article-title":"Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.","volume":"60","author":"Luetkemeyer","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R8-20250808","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1097\/00002030-200111090-00022","article-title":"Impaired absorption of rifabutin by concomitant administration of didanosine.","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"R9-20250808","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1086\/497835","article-title":"Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.","volume":"41","author":"Guti\u00e9rrez","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R10-20250808","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.tpj.6500338","article-title":"Pharmacogenetics and the concept of individualized medicine.","volume":"6","author":"Shastry","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"R11-20250808","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1101\/gr.3761405","article-title":"On the probability that a novel variant is a disease-causing mutation.","volume":"15","author":"Mitchell","year":"2005","journal-title":"Genome Res"},{"key":"R12-20250808","first-page":"110","article-title":"Determinants of aspirin metabolism in healthy men and women: effects of dietary inducers of UDP-glucuronosyltransferases.","volume":"4","author":"Navarro","year":"2011","journal-title":"J Nutrigenet Nutrigenomics"},{"key":"R13-20250808","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/QAI.0000000000000473","article-title":"HIV-1 subtype B\/B\u2019 and baseline drug resistance mutation are associated with virologic failure: a multicenter cohort study in China.","volume":"68","author":"Li","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R14-20250808","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1365-2125.2012.04288.x","article-title":"Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.","volume":"74","author":"Sukasem","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"R15-20250808","doi-asserted-by":"crossref","first-page":"e0130583","DOI":"10.1371\/journal.pone.0130583","article-title":"Effect of CYP2B6 gene polymorphisms on efavirenz plasma concentrations in Chinese patients with HIV infection.","volume":"10","author":"Meng","year":"2015","journal-title":"PLoS One"},{"key":"R16-20250808","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1093\/jac\/dky190","article-title":"Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals.","volume":"73","author":"de Almeida","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R17-20250808","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.","volume":"306","author":"Ward","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R18-20250808","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-007-0412-3","article-title":"High prevalence of the CYP2B6 516G\u2013>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV\/AIDS outpatients in Zimbabwe.","volume":"64","author":"Nyakutira","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"R19-20250808","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1089\/omi.2017.0078","article-title":"CYP2B6 haplotype predicts Efavirenz plasma concentration in black South African HIV-1-infected children: a longitudinal pediatric pharmacogenomic study.","volume":"21","author":"Reay","year":"2017","journal-title":"OMICS"},{"key":"R20-20250808","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/FTD.0b013e31824868f3","article-title":"Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.","volume":"34","author":"Heil","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R21-20250808","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/cpt.1477","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2B6 and Efavirenz-containing antiretroviral therapy.","volume":"106","author":"Desta","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R22-20250808","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cpt.2166","article-title":"PharmVar GeneFocus: CYP2B6.","volume":"110","author":"Desta","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R23-20250808","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/499364","article-title":"Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an adult AIDS clinical trials group study.","volume":"42","author":"Ribaudo","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R24-20250808","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bcp.12590","article-title":"Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.","volume":"80","author":"Sinxadi","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"R25-20250808","doi-asserted-by":"crossref","first-page":"e26614","DOI":"10.1097\/MD.0000000000026614","article-title":"Distribution of alleles, genotypes and haplotypes of the CYP2B6 (rs3745274; rs2279343) and CYP3A4 (rs2740574) genes in the Malian population: implication for pharmacogenetics.","volume":"100","author":"Kassogue","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"R26-20250808","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/bioinformatics\/btl268","article-title":"SNPStats: a web tool for the analysis of association studies.","volume":"22","author":"Sol\u00e9","year":"2006","journal-title":"Bioinformatics"},{"key":"R27-20250808","doi-asserted-by":"crossref","first-page":"11937","DOI":"10.1016\/S0021-9258(17)44323-7","article-title":"Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver.","volume":"258","author":"Waxman","year":"1983","journal-title":"J Biol Chem"},{"key":"R28-20250808","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1472-8206.1993.tb00219.x","article-title":"Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism.","volume":"7","author":"Seree","year":"1993","journal-title":"Fundam Clin Pharmacol"},{"key":"R29-20250808","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0090-9556(25)08439-9","article-title":"Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Dual pathways involving novel ortho ring-hydroxylation by CYP2B.","volume":"22","author":"Dehal","year":"1994","journal-title":"Drug Metab Dispos"},{"key":"R30-20250808","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1081\/DMR-100101942","article-title":"The role of CYP2B6 in human xenobiotic metabolism.","volume":"31","author":"Ekins","year":"1999","journal-title":"Drug Metab Rev"},{"key":"R31-20250808","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R32-20250808","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1089\/aid.2018.0062","article-title":"CYP2B6 genetic polymorphisms, depression, and viral suppression in adults living with HIV initiating Efavirenz-containing antiretroviral therapy regimens in Uganda: pooled analysis of two prospective studies.","volume":"34","author":"Chang","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R33-20250808","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/jac\/dku088","article-title":"Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.","volume":"69","author":"Haas","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R34-20250808","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS clinical trials group study.","volume":"202","author":"Ribaudo","year":"2010","journal-title":"J Infect Dis"},{"key":"R35-20250808","doi-asserted-by":"crossref","first-page":"692234","DOI":"10.3389\/fgene.2021.692234","article-title":"CYP2B6 functional variability in drug metabolism and exposure across populations-implication for drug safety, dosing, and individualized therapy.","volume":"12","author":"Langmia","year":"2021","journal-title":"Front Genet"},{"key":"R38-20250808","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.clpt.6100072","article-title":"Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.","volume":"81","author":"Rotger","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R39-20250808","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12981-015-0052-0","article-title":"Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study.","volume":"12","author":"Oluka","year":"2015","journal-title":"AIDS Res Ther"},{"key":"R40-20250808","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/em.10199","article-title":"Increased transcriptional activity of the CYP3A4*1B promoter variant.","volume":"42","author":"Amirimani","year":"2003","journal-title":"Environ Mol Mutagen"},{"key":"R41-20250808","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12936-017-1914-9","article-title":"Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.","volume":"16","author":"Mutagonda","year":"2017","journal-title":"Malar J"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T12:01:21Z","timestamp":1754654481000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000477","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,22]]}}}